Concurrent radiochemotherapy in advanced hypopharyngeal cancer

被引:12
|
作者
Krstevska, Valentina [1 ]
Stojkovski, Igor [1 ]
Lukarski, Dusko [2 ]
机构
[1] Univ Clin Radiotherapy & Oncol, Dept Head & Neck Canc, Skopje, North Macedonia
[2] Univ Clin Radiotherapy & Oncol, Dept Radiat Phys, Skopje, North Macedonia
关键词
SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; ONCOLOGY GROUP RTOG; RADIATION-THERAPY; NECK-CANCER; ADVANCED LARYNGEAL; RANDOMIZED-TRIAL; ACCELERATED RADIOTHERAPY; EUROPEAN-ORGANIZATION; ORGAN PRESERVATION;
D O I
10.1186/1748-717X-5-39
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Concurrent platinum-based radiochemotherapy has been recommended as a standard of care in patients with locally advanced squamous cell head and neck carcinomas. Unfortunately, there is a lack of level one evidence on best treatment approach for advanced hypopharyngeal cancer. This report aims to summarize the results of our study on concurrent radiochemotherapy in patients with advanced hypopharyngeal cancer. Methods: A retrospective analysis of 41 patients with stage III-IV hypopharyngeal cancer was performed. All patients were treated with three dimensional conformal radiotherapy and received 70 Gy in 35 fractions (2 Gy per fraction, 5 fractions per week). In dependence of the period when radiotherapy was realized, two different treatment techniques were used. Concurrent chemotherapy consisted of cisplatin 30 mg/m(2) given on a weekly basis. Results: The median age was 52 years (range 29-70). Stage IV disease was recognized in 73.2% of the patients. Complete response rates at the primary site and at the metastatic neck lymph nodes were 68.3% and 36.6%, respectively. A complete composite response was present in 27 patients (65.9%). Median follow-up was 13 months (range 7-36). Distant metastases as initial failure occurred in 7 patients (46.7%). The 2-year local relapse-free survival and regional relapse-free survival rates were 55.2% and 75.8%, respectively. The 2-year locoregional relapse-free survival rate was 51.3%. The 2-year disease-free survival and overall survival rates were 29.3% and 32.8%, respectively. Confluent mucositis was developed in 46.3% of patients. Leucopenia grade 1 was the most frequent hematological toxicity. The median weight loss at the end of treatment was 12% (range 5-21). The worst grade of late toxicity was most commonly pronounced in the skin and in the subcutaneous tissue. Conclusions: Based on unsatisfactory results in our study we suggest that the use of sequential radiochemotherapy or chemotherapy given concomitantly with altered fractionation radiotherapy with the implementation of intensity-modulated radiotherapy as radiotherapy technique could represent treatment approaches able to improve outcome in patients with advanced hypopharyngeal cancer.
引用
收藏
页数:11
相关论文
共 50 条
  • [32] CONCURRENT CHEMORADIOTHERAPY IMPROVES SURVIVAL IN PATIENTS WITH HYPOPHARYNGEAL CANCER
    Paximadis, Peter
    Yoo, George
    Lin, Ho-Sheng
    Jacobs, John
    Sukari, Ammar
    Dyson, Greg
    Christensen, Michael
    Kim, Harold
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (04): : 1515 - 1521
  • [33] First results of concurrent preoperative radiochemotherapy of locally advanced rectal canter
    Küchenmeister, U
    Kirchner, R
    Mellert, J
    Klautke, G
    Mücke, R
    Hopt, UT
    Fietkau, R
    STRAHLENTHERAPIE UND ONKOLOGIE, 2000, 176 (12) : 560 - 566
  • [34] Clinical value of concurrent radiochemotherapy in cervical cancer and comparison of ultrasonography findings before and after radiochemotherapy
    Yan, W. M.
    Li, X. Z.
    Yu, Z. L.
    Zhang, J.
    Sun, X. G.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (02) : 3633 - 3639
  • [35] Organ preservation surgery for advanced hypopharyngeal cancer
    Hirano, Shigeru
    Tateya, Ichiro
    Kitamura, Morimasa
    Kada, Shinpei
    Ishikawa, Seiji
    Kanda, Tomoko
    Tanaka, Shinzo
    Ito, Juichi
    ACTA OTO-LARYNGOLOGICA, 2010, 130 : 50 - 55
  • [36] The role of chemotherapy for advanced oro and hypopharyngeal cancer
    Kohno, N
    AURIS NASUS LARYNX, 2004, 31 (02) : 113 - 118
  • [37] Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer
    Kathrin Dellas
    Thomas Höhler
    Thomas Reese
    Florian Würschmidt
    Erik Engel
    Claus Rödel
    Wolfgang Wagner
    Michael Richter
    Dirk Arnold
    Jürgen Dunst
    Radiation Oncology, 8
  • [38] Toxicity of Concurrent Radiochemotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Systematic Review of the Literature
    Koning, Caro C.
    Wouterse, Sanne J.
    Daams, Joost G.
    Uitterhoeve, Lon L.
    van den Heuvel, Michel M.
    Belderbos, Jose S.
    CLINICAL LUNG CANCER, 2013, 14 (05) : 481 - 487
  • [39] TIMING AND PATTERNS OF DISEASE PROGRESSION FOLLOWING CONCURRENT RADIOCHEMOTHERAPY IN PATIENTS WITH UNRESECTABLE LOCALLY-ADVANCED PANCREAS CANCER
    Parlak, C.
    Guler, O. C.
    Ozyilkan, O.
    Topkan, E.
    ANNALS OF ONCOLOGY, 2012, 23 : 238 - 238
  • [40] Chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer
    Tai, Shyh-Kuan
    Yang, Muh-Hwa
    Wang, Ling-Wei
    Tsai, Tung-Lung
    Chu, Pen-Yuan
    Wang, Yi-Feng
    Huang, Jui-Lin
    Chang, Shyue-Yih
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (08) : 521 - 527